Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

NCT00625664 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

337

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Neoplasms

Interventions

DRUG: larotaxel (XRP9881)
DRUG: gemcitabine
DRUG: cisplatin

Sponsor

Sanofi